181 66

Full metadata record

DC FieldValueLanguage
dc.contributor.author배상철-
dc.date.accessioned2022-11-02T06:26:22Z-
dc.date.available2022-11-02T06:26:22Z-
dc.date.issued2021-02-
dc.identifier.citationLUPUS SCIENCE & MEDICINE, v. 8, no. 1, article no. e000433en_US
dc.identifier.issn2053-8790en_US
dc.identifier.urihttps://lupus.bmj.com/content/8/1/e000433en_US
dc.identifier.urihttps://repository.hanyang.ac.kr/handle/20.500.11754/176232-
dc.description.abstractThe Addressing Lupus Pillars for Health Advancement (ALPHA) Project is a global consensus effort to identify, prioritise and address top barriers in lupus impacting diagnosis, care, treatment and research. To conduct this process, the ALPHA Project convened a multistakeholder Global Advisory Committee (GAC) of lupus experts and collected input from global audiences, including patients. In phase I, the ALPHA Project used expert interviews and a global survey of lupus experts to identify and categorise barriers into three overarching pillars: drug development, clinical care and access to care. In phase II, reported here, the GAC developed recommended actionable solutions to address these previously identified barriers through an in-person stakeholder meeting, followed by a two-round scoring process. Recommendations were assessed for feasibility, impact and timeline for implementation (FIT), where potential FIT component values were between 1 and 3 and total scores were between 3 and 9. Higher scores represented higher achievability based on the composite of the three criteria. Simplifying and standardising outcomes measures, including steroid sparing as an outcome (drug development) and defining the lupus spectrum (clinical care) ranked as the highest two priority solutions during the GAC meeting and received high FIT scores (7.67 and 7.44, respectively). Leveraging social media (access to care) received the highest FIT score across all pillars (7.86). Cross-cutting themes of many solutions include leveraging digital technology and applying specific considerations for special populations, including paediatrics. Implementing the recommendations to address key barriers to drug development, clinical care and access to care is essential to improving the quality of life of adults and children with lupus. Multistakeholder collaboration and guidance across existing efforts globally is warranted.en_US
dc.description.sponsorshipThe Addressing Lupus Pillars for Health Advancement Project was launched in partnership with founding partner EMD Serono Research & Development Institute, Inc. (a business of Merck KGaA, Darmstadt, Germany) and through additional support by GlaxoSmithKline. Aurinia Pharmaceuticals and Mallinckrodt Pharmaceuticals provided additional sponsorship.en_US
dc.languageenen_US
dc.publisherBMJ PUBLISHING GROUPen_US
dc.subjectlupus erythematosus; systemic; autoimmunity; autoimmune diseasesen_US
dc.titleThe ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and researchen_US
dc.typeArticleen_US
dc.relation.no1-
dc.relation.volume8-
dc.identifier.doi10.1136/lupus-2020-000433en_US
dc.relation.page0-0-
dc.relation.journalLUPUS SCIENCE & MEDICINE-
dc.contributor.googleauthorTse, Karin-
dc.contributor.googleauthorSangodkar, Sanjyot-
dc.contributor.googleauthorBloch, Lauren-
dc.contributor.googleauthorArntsen, Kathleen-
dc.contributor.googleauthorBae, Sang-Cheol-
dc.contributor.googleauthorBruce, Ian N.-
dc.contributor.googleauthorConnolly-Strong, Erin-
dc.contributor.googleauthorCostenbader, Karen H.-
dc.contributor.googleauthorDickerson, Bradley-
dc.contributor.googleauthorDorner, Thomas-
dc.relation.code2021006212-
dc.sector.campusS-
dc.sector.daehakCOLLEGE OF MEDICINE[S]-
dc.sector.departmentDEPARTMENT OF MEDICINE-
dc.identifier.pidscbae-


qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

BROWSE